Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Therapeutics in Services Agreement with National Institute of Aging

NEW YORK, May 7 - Lynx Therapeutics of Hayward, Calif., today announced that it has entered a service agreement with the National Institute on Aging of the NIH to study stem cell gene expression using its MPSS technology.


Lynx will receive payments for the services it performs on samples provided by the NIA under this agreement. Further details were not provided.


The company said that an analysis of human astrocyte precursor cells undertaken for Cue Therapeutics helped propel the NIA to initiate analysis of additional human stem cells using Lynx's massively parallel signature sequencing technology.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.